1,184 results on '"Di Maio, Massimo"'
Search Results
2. Author’s Reply to Ma et al.: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis”
3. Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)
4. A neuroligin-2-YAP axis regulates progression of pancreatic intraepithelial neoplasia
5. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
6. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects
7. Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer
8. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
9. Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project
10. The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project
11. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies
12. Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study
13. Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes
14. Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group
15. Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications
16. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
17. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
18. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
19. Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments
20. Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
21. Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendations
22. Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer
23. Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
24. Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
25. Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
26. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer
27. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis
28. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors
29. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
30. Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: A systematic literature review and meta-analysis.
31. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
32. Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial
33. New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
34. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
35. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
36. Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review
37. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma
38. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study
39. Clinical Trials and Methodology of Cancer Research
40. The need for optimal crossover in trials testing the anticipation of treatments: A methodological and ethical issue
41. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma
42. Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer
43. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
44. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate
45. Second medical opinion in oncological setting
46. Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis
47. A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system
48. Emergence of multidrug-resistant Staphylococcus haemolyticus in neonatal intensive care unit in Southern France, a genomic study.
49. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications
50. Challenges and controversies in resectable non-small cell lung cancer:a clinician's perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.